Literature DB >> 10102078

Serum levels of insulin-like growth factor binding proteins in Ecuadorean children with growth hormone insensitivity.

C P Burren1, D Wanek, S Mohan, P Cohen, J Guevara-Aguirre, R G Rosenfeld.   

Abstract

Although insulin-like growth factor binding proteins (IGFBPs) are known to be important modulators of the action of insulin-like growth factors (IGFs), regulation of their production in vivo is not completely understood. Serum concentrations of IGFBP-3, -4 and -5 and acid-labile subunit (ALS) were therefore examined in 20 children with growth hormone (GH) insensitivity before and after 6 months of therapy with recombinant human IGF-I (80 or 120 micrograms/kg twice daily). The IGFBP concentrations in these children were compared with those in 62 GH-deficient children receiving GH therapy for 3 months. Serum levels of IGFBP-3, -4 and -5 and ALS all increased significantly (p < 0.0001) in GH-deficient children in response to GH therapy, whereas no significant increases occurred in the children with GH insensitivity. These findings indicate that GH is responsible for the regulation of serum levels of IGFBP-3, -4 and -5 and ALS, and that IGF-I does not directly regulate the concentrations of these circulating IGFBPs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102078     DOI: 10.1111/j.1651-2227.1999.tb14387.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  6 in total

Review 1.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

2.  Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty.

Authors:  S Zucchini; E Scarano; L Baldazzi; L Mazzanti; P Pirazzoli; E Cacciari
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

3.  Mapping quantitative trait loci that influence serum insulin-like growth factor binding protein-5 levels in F2 mice (MRL/MpJ X SJL/J).

Authors:  Subburaman Mohan; Godfred Masinde; Xinmin Li; David J Baylink
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

4.  Skeletal response of male mice to anabolic hormone therapy in the absence of the Igfals gene.

Authors:  Oran D Kennedy; Hui Sun; Yingjie Wu; Hayden-William Courtland; Garry A Williams; Luis Cardoso; Jelena Basta-Pljakic; Mitchell B Schaffler; Shoshana Yakar
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

5.  Genetic Defects in the Growth Hormone-IGF-I Axis Causing Growth Hormone Insensitivity and Impaired Linear Growth.

Authors:  Martin O Savage; Vivian Hwa; Alessia David; Ron G Rosenfeld; Louise A Metherell
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-12       Impact factor: 5.555

Review 6.  Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development.

Authors:  Xavier Escoté; Saioa Gómez-Zorita; Miguel López-Yoldi; Iñaki Milton-Laskibar; Alfredo Fernández-Quintela; J Alfredo Martínez; María J Moreno-Aliaga; María P Portillo
Journal:  Int J Mol Sci       Date:  2017-08-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.